

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A03/2016 OS WB

DISPATCHED ON 05TH APRIL 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1,A32; B8, B60; Cw7, Cw10; DR4, DR17; DQ2, DQ8

| | | | Summary of Results | | | | | | | | |
|--|-----------------------|-------------------|--------------------|---------------------|-----------------|-----------------|-----------------|-----------------|-----------------|---------------------|---|
| | | | PBL/T-Cells | | | | B-Cells | | | | |
| Total tested | | | 19 | 18 | 19 | 19 | 13 | 13 | 13 | 12 | |
| Positive | | | 0 | 11 | 15 | 3 | 0 | 10 | 13 | 6 | |
| Negative | | | 19 | 7 | 4 | 16 | 13 | 3 | 0 | 6 | |
| NT/Equivocal | | | 0 | 1 | 0 | 0 | 3 | 3 | 3 | 4 | |
| % Positive | | | 0.0% | 61.1% | 78.9% | 15.8% | 0.0% | 76.9% | 100.0% | 50.0% | |
| % Negative | | | 100.0% | 38.9% | 21.1% | 84.2% | 100.0% | 23.1% | 0.0% | 50.0% | |
| Consensus | | | Negative | Not Assessed | Positive | Negative | Negative | Positive | Positive | Not Assessed | |
| HLA Antibody Specificity (Defined By CDC) | | | B5 | A1 | A1,A11,Cw4+ | A10+ | B5 | A1 | A1,A11,Cw4+ | A10+ | |
| | | | Without DTT | | | | Without DTT | | | | |
| Lab No. | PBL/T Cell Assessment | B Cell Assessment | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Comments |
| 101 | YES | YES | Negative | Positive | Positive | Negative | Negative | Positive | Positive | Negative | |
| 114 | YES | YES | Negative | Positive | Positive | Negative | Negative | Positive | Positive | Positive | |
| 116 | YES | YES | Negative | Positive | Positive | Positive | NT | NT | NT | NT | Viability of the B cells does not meet the criteria for the test |
| 117 | YES | NO | Negative | Positive | Positive | Negative | | | | | |
| 133 | YES | YES | Negative | Negative | Positive | Negative | NT | NT | NT | NT | B cell viability too low |
| 136 | YES | NO | Negative | Negative | Positive | Negative | | | | | |
| 145 | YES | YES | Negative | Positive | Positive | Negative | Negative | Positive | Positive | Negative | The evaluation of XM with B cells was difficult due to high percentage of dead cells (background) |
| 149 | YES | NO | Negative | Positive | Positive | Negative | | | | | |
| 162 | YES | YES | Negative | Positive | Positive | Negative | Negative | Positive | Positive | Positive | |
| 163 | YES | YES | Negative | Positive | Positive | Positive | Negative | Positive | Positive | Positive | |
| 186 | YES | YES | Negative | Positive | Positive | Positive | Negative | Positive | Positive | Positive | |
| 204 | YES | YES | Negative | Equivocal | Positive | Negative | NT | NT | NT | NT | Very low B cell viability |
| 206 | YES | YES | Negative | Positive | Negative | Negative | Negative | Positive | Positive | Negative | |
| 212 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Negative | |
| 227 | YES | YES | Negative | Negative | Negative | Negative | Negative | Positive | Positive | NT | Serum 4 has technical failure on B cell |
| 268 | YES | YES | Negative | Positive | Positive | Negative | Negative | Positive | Positive | Positive | |
| 284 | YES | YES | Negative | Negative | Positive | Negative | Negative | Negative | Positive | Negative | |
| 311 | YES | YES | Negative | Negative | Positive | Negative | Negative | Positive | Positive | Positive | |
| 315 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Serum 3 is only positive on par and detected at 1/2 but not on the concentrated serum |

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A03/2016 OS WB

DISPATCHED ON 05TH APRIL 2016

| Lab No. | PBL/T-cell without DTT | | | | B-cell without DTT | | | | Cell viability % | | |
|---------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|------------------|---------|---------|
| | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | PBL | T-cells | B-cells |
| 101 | 1 | 8 | 8 | 1 | 1 | 6 | 8 | 1 | 100 | 100 | |
| 114 | 1 | 4 | 6 | 1 | 2 | 6 | 8 | 6 | | | |
| 116 | 1 | 4-6 | 6 | 1-2 | NT | NT | NT | NT | 70 | 90 | 50 |
| 117 | 1 | 4 | 4 | 1 | | | | | | | |
| 133 | 0 | 0 | 8 | 0 | NT | NT | NT | NT | | 70 | 10 |
| 136 | 1 | 2 | 6 | 1 | | | | | | 98 | |
| 145 | | 6-8 | 4-6 | | | 8 | 6-8 | | | 85 | 100 |
| 149 | | | | | | | | | 70 | | |
| 162 | | 4 | 6 | | | 6/8 | 8 | 8 | | 100 | 100 |
| 163 | 1 | 8 | 8 | 8 | 1 | 8 | 8 | 8 | | 90 | 80 |
| 186 | 0 | 6 | 8 | 4 | 0 | 8 | 8 | 6 | | 99 | 99 |
| 204 | 1 | 4 | 6 | 2 | NT | NT | NT | NT | | 95 | 20 |
| 206 | 1 | 6 | 1 | 1 | 1 | 8 | 8 | 1 | | 90 | 90 |
| 212 | | | | | | | | | 99 | 97 | |
| 227 | | | | | | 8 | 8 | | 90 | | |
| 268 | 1 | 6 | 6 | 1 | 1 | 2 | 2 | 2 | | 90 | 70 |
| 284 | 1 | 1 | 4 | 1 | 1 | 1 | 8 | 1 | | 98 | 87 |
| 311 | 1 | 1 | 8 | 1 | 1 | 8 | 8 | 8 | | 85 | 85 |
| 315 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 1 | | 80 | 80 |

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A03/2016 OS WB

DISPATCHED ON 05TH APRIL 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1,A32; B8, B60; Cw7, Cw10; DR4, DR17; DQ2, DQ8

| | | | Summary of Results | | | | | | | | |
|--|-----------------------|-------------------|--------------------|---------------------|-----------------|-----------------|-----------------|-----------------|-----------------|---------------------|--|
| | | | PBL/T-Cells | | | | B-Cells | | | | |
| Total tested | | | 16 | 15 | 16 | 16 | 12 | 12 | 12 | 11 | |
| Positive | | | 0 | 7 | 12 | 3 | 0 | 9 | 11 | 5 | |
| Negative | | | 16 | 8 | 4 | 13 | 12 | 3 | 1 | 6 | |
| NT/Equivocal | | | 0 | 1 | 0 | 0 | 3 | 3 | 3 | 4 | |
| % Positive | | | 0.0% | 46.7% | 75.0% | 18.8% | 0.0% | 75.0% | 91.7% | 45.5% | |
| % Negative | | | 100.0% | 53.3% | 25.0% | 81.3% | 100.0% | 25.0% | 8.3% | 54.5% | |
| Consensus | | | Negative | Not Assessed | Positive | Negative | Negative | Positive | Positive | Not Assessed | |
| HLA Antibody Specificity (Defined By CDC) | | | B5 | A1 | A1,A11,Cw4+ | A10+ | B5 | A1 | A1,A11,Cw4+ | A10+ | |
| | | | With DTT | | | | With DTT | | | | |
| Lab No. | PBL/T Cell Assessment | B Cell Assessment | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Serum 1 | Serum 2 | Serum 3 | Serum 4 | Comments |
| 101 | YES | YES | Negative | Positive | Positive | Negative | Negative | Positive | Positive | Negative | |
| 114 | YES | YES | Negative | Positive | Positive | Negative | Negative | Positive | Positive | Positive | |
| 116 | YES | YES | Negative | Positive | Positive | Positive | NT | NT | NT | NT | Viability of the B cells does not meet the criteria for the test B cell viability too low |
| 133 | YES | YES | Negative | Negative | Positive | Negative | NT | NT | NT | NT | |
| 149 | YES | NO | Negative | Negative | Positive | Negative | | | | | |
| 162 | YES | YES | Negative | Positive | Positive | Negative | Negative | Positive | Positive | Positive | |
| 163 | YES | YES | Negative | Positive | Positive | Positive | Negative | Positive | Positive | Positive | |
| 186 | YES | YES | Negative | Positive | Positive | Positive | Negative | Positive | Positive | Positive | |
| 204 | YES | YES | Negative | Equivocal | Positive | Negative | NT | NT | NT | NT | Very low B cell viability |
| 206 | YES | YES | Negative | Negative | Negative | Negative | Negative | Positive | Positive | Negative | |
| 212 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| 227 | YES | YES | Negative | Negative | Negative | Negative | Negative | Positive | Positive | NT | Serum 4 has technical failure on B cell |
| 268 | YES | YES | Negative | Positive | Positive | Negative | Negative | Positive | Positive | Negative | |
| 284 | YES | YES | Negative | Negative | Positive | Negative | Negative | Negative | Positive | Negative | |
| 311 | YES | YES | Negative | Negative | Positive | Negative | Negative | Positive | Positive | Positive | |
| 315 | YES | YES | Negative | Negative | Negative | Negative | Negative | Negative | Positive | Negative | Serum 3 is only positive on par and detected at 1/2 but not on the concentrated serum |

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A03/2016 OS WB

DISPATCHED ON 05TH APRIL 2016

| Lab No. | PBL/T-cell with DTT | | | | B-cell with DTT | | | | Cell viability % | | |
|---------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|------------------|---------|---------|
| | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | Serum 1 reaction strength | Serum 2 reaction strength | Serum 3 reaction strength | Serum 4 reaction strength | PBL | T-cells | B-cells |
| 101 | 1 | 8 | 8 | 1 | 1 | 6 | 8 | 1 | 100 | 100 | |
| 114 | 1 | 4 | 4 | 1 | 2 | 6 | 8 | 4 | | | |
| 116 | 1 | 2-6 | 2-6 | 1-2 | NT | NT | NT | NT | 90 | 50 | |
| 133 | 0 | 0 | 8 | 0 | NT | NT | NT | NT | 70 | 10 | |
| 149 | | | | | | | | | 70 | | |
| 162 | | 4 | 6 | | | 6/8 | 8 | 6/8 | 100 | 100 | |
| 163 | 1 | 8 | 8 | 4 | 1 | 8 | 8 | 6 | 90 | 80 | |
| 186 | 0 | 8 | 8 | 4 | 0 | 6 | 8 | 2 | 99 | 99 | |
| 204 | 1 | 4 | 6 | 2 | NT | NT | NT | NT | 95 | 20 | |
| 206 | 1 | 1 | 1 | 1 | 1 | 8 | 8 | 1 | 90 | 90 | |
| 212 | | | | | | | | | 99 | 97 | |
| 227 | | | | | | 8 | 8 | | 90 | | |
| 268 | 1 | 6 | 8 | 1 | 1 | 4 | 4 | 1 | 90 | 70 | |
| 284 | 1 | 1 | 4 | 1 | 1 | 1 | 8 | 1 | 98 | 87 | |
| 311 | 1 | 1 | 8 | 1 | 1 | 8 | 8 | 6 | 85 | 85 | |
| 315 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 1 | 80 | 80 | |